

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

www.thelancet.com/microbe Vol 4 April 2023

Articles

Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

Zhi-Rong Yang*, Yi-Wen Jiang*, Fu-Xiao Li, Di Liu, Teng-Fei Lin, Zi-Yi Zhao, Chang Wei, Qian-Yi Jin, Xi-Miao Li, Yuan-Xi Jia, Feng-Cai Zhu, Zu-Yao Yang, Feng Sha, Zi-Jian Feng, Jin-Ling Tang

Summary

Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness and death is uncertain due to the rarity of data in individual trials. How well the antibody concentrations can predict the efficacy is also uncertain. We aimed to assess the efficacy of these vaccines in preventing SARS-CoV-2 infections of different severities and the dose–response relationship between the antibody concentrations and efficacy.

Methods We did a systematic review and meta-analysis of randomised controlled trials (RCTs). We searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, WHO, bioRxiv, and medRxiv for papers published between Jan 1, 2020 and Sep 12, 2022. RCTs on the efficacy of SARS-CoV-2 vaccines were eligible. Risk of bias was assessed using the Cochrane tool. A frequentist, random-effects model was used to combine efficacy for common outcomes (ie, symptomatic and asymptomatic infections) and a Bayesian random-effects model was used for rare outcomes (ie, hospital admission, severe infection, and death). Potential sources of heterogeneity were investigated. The doseresponse relationships of neutralising, spike-specific IgG and receptor binding domain-specific IgG antibody titres with efficacy in preventing SARS-CoV-2 symptomatic and severe infections were examined by meta-regression. This systematic review is registered with PROSPERO, CRD42021287238.

Findings 28 RCTs (n=286915 in vaccination groups and n=233236 in placebo groups; median follow-up 1–6 months after last vaccination) across 32 publications were included in this review. The combined efficacy of full vaccination was 44.5% (95% CI 27.8-57.4) for preventing asymptomatic infections, 76.5% (69.8-81.7) for preventing symptomatic infections, 95.4% (95% credible interval 88.0-98.7) for preventing hospitalisation, 90.8% (85.5-95.1) for preventing severe infection, and 85.8% (68.7-94.6) for preventing death. There was heterogeneity in the efficacy of SARS-CoV-2 vaccines against asymptomatic and symptomatic infections but insufficient evidence to suggest whether the efficacy could differ according to the type of vaccine, age of the vaccinated individual, and between-dose interval (p>0.05 for all). Vaccine efficacy against symptomatic infection waned over time after full vaccination, with an average decrease of 13.6% (95% CI 5.5-22.3; p=0.0007) per month but can be enhanced by a booster. We found a significant non-linear relationship between each type of antibody and efficacy against symptomatic and severe infections. The risk of bias was low in most studies.

Interpretation The efficacy of SARS-CoV-2 vaccines is higher for preventing severe infection and death than for preventing milder infection. Vaccine efficacy wanes over time but can be enhanced by a booster. Higher antibody titres are associated with higher estimates of efficacy but precise predictions are difficult due to large unexplained heterogeneity. These findings provide an important knowledge base for interpretation and application of future studies on these issues.

Funding Shenzhen Science and Technology Programs.

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Introduction

SARS-CoV-2 vaccines have been rapidly developed, evaluated in randomised controlled trials (RCTs), and used worldwide.¹ Early systematic reviews of RCTs showed that the vaccines could prevent SARS-CoV-2 infections.²⁻⁵ However, these reviews did not fully examine the efficacy of vaccines in preventing severe infections and deaths, partly due to there being none or a small number of these events in individual trials.² How vaccine efficacy changed over time in RCTs also remained unclear. Conversely, real-world observational studies suggested that current vaccines will be unlikely to stop the COVID-19 pandemic as they were much less effective in preventing infection than they were in preventing severe infection and death, and their effectiveness waned quickly over time.⁶ If these findings



Lancet Microbe 2023; 4: e236-46

Published Online February 28, 2023 https://doi.org/10.1016/ S2666-5247(22)00390-1 *Contributed equally

Center for Biomedical Information Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. Shenzhen, China (Z-R Yang PhD, Y-W Jiang PhD, F-X Li PhD, D Liu PhD, T-F Lin PhD, 7-Y Zhao MPH_C Wei MSc Y-X Jia PhD, F Sha PhD, Prof J-L Tang PhD); Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK (Z-R Yang); School of Mathematics, Sun Yat-sen University, Guangzhou, China (Q-Y Jin BSc, X-M Li BSc); **Department of Vaccine Clinical** Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China (Prof F-C Zhu MSc); Division of Epidemiology, JC School of Public Health and Primary Care. The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China (Z-Y Yang PhD): Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China (Prof Z-J Feng MMed); Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou, China (Prof J-L Tang)

Correspondence to: Feng Sha, Center for Biomedical Information Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China

feng.sha@siat.ac.cn

or

Zu-Yao Yang, Division of Epidemiology, JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, 999077, China zyang@cuhk.edu.hk

Research in context

Evidence before this study

Since 2020, SARS-CoV-2 vaccines have been quickly developed, evaluated in randomised controlled trials (RCTs), and used worldwide. We did a comprehensive search of systematic reviews from PubMed publication published between Jan 1, 2020, and June 30, 2022, using search terms related to SARS-CoV-2, vaccines, and systematic reviews with no restrictions on language of publication. There are systematic reviews of RCTs on vaccine efficacy in preventing infections published before November, 2021. However, there remain uncertainties in the efficacy of vaccines in preventing severe infections and in the waning of efficacy, and many new trials were published after these reviews. Furthermore, in many scenarios where the efficacy is untested, antibody concentrations induced by SARS-CoV-2 vaccines are often used to predict and compare vaccine efficacy. However, the foundation of such predictions or comparisons has not been firmly established. We did this systematic review and metaanalysis to address these issues.

Added value of this study

We found moderate-quality evidence that vaccine efficacy was modest in preventing mild infection, but high in preventing severe infection and death. The efficacy of full vaccination waned quickly over time but can be enhanced by a booster. There was insufficient evidence to suggest whether the efficacy might differ according to the type of vaccine, age of the vaccinated individual, and between-dose interval. Although there was a significant non-linear dose-response relationship between the antibodies and efficacy against symptomatic and severe infection, there remained considerable heterogeneity in the efficacy which cannot be explained by antibody concentrations.

Implications of all the available evidence

Our findings suggested that SARS-CoV-2 vaccines are insufficiently efficacious in preventing infections and therefore cannot stop the pandemic alone. However, all the vaccines can be used to effectively prevent severe infection and death. Waning of vaccine efficacy makes it important to time vaccination in relation to an anticipated outbreak. Moreover, the antibody-efficacy relationship is complex and should be used with caution to predict efficacy in uncertain situations. Since the vaccines can no longer be assessed in previous predominant variants that are now extinct, this systematic review provides an irreplaceable reference for comparisons with and interpretation of future studies assessing vaccine efficacy in new scenarios, such as booster vaccine regimens, new SARS-CoV-2 vaccines, and future SARS-CoV-2 variants.

are true, the primary goal of vaccination strategies should be reset to reducing the risk of severe infection and death and the timing of vaccination should also be optimised.⁷ However, real-world studies are susceptible to bias.

Furthermore, SARS-CoV-2 antibody concentrations are often used to predict or compare the efficacy of the vaccines for such important scenarios as new vaccines, booster dose, heterologous vaccination, waning efficacy, and other vaccine regimens for which efficacy trials are not immediately or will never be available.8 The validity of such predictions or comparisons relies heavily on the assumption that there is a close dose-response relationship between antibodies and the efficacy, but this relationship has not been firmly established.8.9 To address this issue, a preferable method is dose-response analyses within individual trials, but such analyses using paired data on antibody and efficacy collected repeatedly within the same study essentially do not exist in published trials.10 Meta-regression analysis of data from different trials provides a possible, approximate solution to the problem.

Finally, many new trials have been published since previous systematic reviews were done that included all available efficacy trials up to November, 2021.^{2–5} A collection of evidence from all currently available trials will be an important and irreplaceable reference for interpretation and application of results from future studies of SARS-CoV-2 vaccines. We therefore did this systematic review to address two issues: the efficacy of the vaccines in preventing SARS-CoV-2 infections of different degrees of severity and the dose–response relationship between antibody concentrations and efficacy.

Methods

Search strategy and selection criteria

This systematic review and meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (appendix pp 186–92).¹¹ A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library for relevant studies published between Jan 1, 2020, and Sep 12, 2022, with no restrictions on language of publication. We also searched bioRxiv, medRxiv, and the WHO COVID-19 Research Database for grey literature published during the same period. We mainly used search terms related to "SARS-CoV-2", "vaccine", and "trial" (appendix pp 7–11). The reference lists of relevant systematic reviews and included studies were manually scanned to identify additional studies.

Two groups (group one: Y-WJ, T-FL, DL, CW, and Y-XJ, group two: F-XL, X-ML, Q-YJ, and Z-YZ) of investigators screened the literature independently with discrepancies resolved by discussion with a third investigator (Z-RY, FS, Z-YY or J-LT). RCTs (of any language) that assessed the clinical efficacy of SARS-CoV-2 vaccines compared

See Online for appendix

with placebo were eligible. The clinical efficacy outcomes of interest had to be PCR-confirmed SARS-CoV-2 related and included asymptomatic infection, symptomatic infection, hospital admission, severe infection, and death. In this Article, full vaccination is defined as vaccination with a primary vaccine series, and booster is defined as additional doses following full vaccination. Studies were excluded if they: (1) had no data on vaccine efficacy, (2) were a conference abstract, or (3) were duplicate studies. For publications derived from the same study population, only those with the longest follow-up duration were included. Where data on vaccine efficacy and antibodies were not reported in the same study, we identified corresponding previous phase 2 or phase 1 trials on the immunogenicity of the same dose of the vaccine.

This systematic review is registered with PROSPERO, CRD42021287238.

Data analysis

Two investigators (Y-WJ and F-XL) extracted data independently using a pre-designed form. Disagreements were resolved by discussion with a third investigator (Z-RY). The extracted data included details on study design, participants, intervention, control, efficacy outcomes, and antibody titres of neutralising, spikespecific IgG, and receptor binding domain (RBD)-specific IgG after full vaccination. Data on T-cell response to full vaccination were also collected where available. When immunogenicity data were measured repeatedly, we used those collected at the time closest to the starting point of efficacy assessment.

The Cochrane tool (version 1) was used to evaluate the risk of bias of the included efficacy RCTs (appendix p 19).¹² For each domain of the tool, judgement can be high risk of bias, low risk of bias, or unclear risk of bias. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework, which considered risk of bias, indirectness, imprecision, consistency, and publication bias.¹³

A frequentist, random-effects model was used to summarise relative risks (RRs) with 95% CIs for symptomatic and asymptomatic infections. Considering the scarcity of data on hospital admission, severe infections, and deaths as well as moderate heterogeneity across RCTs, a random-effects meta-analysis using a Bayesian binomial-normal hierarchical model (appendix pp 3-4) was done as the primary analysis to estimate the pooled odds ratio (OR) for each outcome (expressed as median posterior estimate and 95% credible interval [CrI]) in R (version 4.2.1).14 A funnel plot and Egger's test were done to assess the risk of publication bias. Vaccine efficacy was calculated as (1–RR)×100% or $(1-OR) \times 100\%$.

To explore the potential effect of risk of bias on our estimates, we did a sensitivity analysis excluding RCTs with high or unclear risk of bias in any domains of the Cochrane tool. Sensitivity analyses were done to examine the stability of Bayesian meta-analysis by varying the previous distributions (appendix p 4).¹⁵ Sensitivity analyses were also done using other methods to account for the scarcity of data, including Peto's OR, OR from a generalised linear mixed model, risk difference, and arcsine difference.^{16,17}

Heterogeneity across RCTs was assessed using I^2 statistics and Q test. For Bayesian meta-analysis, heterogeneity was assessed using posterior predictive p values for τ .¹⁸ Subgroup analyses by types of vaccines, age, injection interval, and variants of concern were done to explore potential sources of heterogeneity where relevant data were available (appendix pp 4–5).

We plotted the change in vaccine efficacy over time for RCTs with repeated measurements of symptomatic infection for discrete time intervals after the final dose of primary vaccine series. The average change in vaccine efficacy over time was assessed using a linear mixed-effects model (appendix p 5).⁶ For other outcomes, no sufficient repeated measurement data were available for this analysis.



Figure 1: Study selection

RCTs=randomised controlled trials.

For the antibody–efficacy relationship, we plotted the efficacy of each type of antibody in preventing symptomatic infections and severe infections. As

antibody assays varied in different studies, antibody titres were transformed to standardised mean difference for comparison. We did a random-effects meta-regression on

A Asymptomatic infection						
	Vaccine name	Days after full vaccination	Vaccination (n/N)	Control (n/N)		Efficacy (95% CI)
mRNA vaccine						
Ali (2021) ²⁰	mRNA-1273	14	21/2139	16/1042		36·1 (-22·0 to 66·5)
Creech (2022) ²²	mRNA-1273	14	9/2644	10/853		71.0 (28.8 to 88.2)
El Sahly (2021) ²⁵	mRNA-12/3	14	214/14/28/	498/14164		5/.4(50.1 to 63.6)
$l^2=8.9\%$ heterogeneity n=0.33			244/190/0	524/10059	•	50.5 (40.2 10 04.9)
Viral vector vaccine						
Kulkarni (2021) ³⁷	SII-ChAdOx1	14	1/1162	1/287		75·3 (-293·7 to 98·5)
Sadoff (2022) ⁴³	Ad26.COV2.S	28	498/19113	669/18924	H H -1	26·3 (17·4 to 34·3)
Sobieszczyk (2021) ⁴⁵	AZD1222	15	104/17662	105/8550		52·1 (37·2 to 63·4)
Voysey (2021) ⁴⁵	AZD1222	14	41/2692	42/2/51		0.2 (-52.9 to 34.9)
$l^2=73.9\%$ heterogeneity n=0.0093			044/40029	01//30512	•	32.1 (5.3 to 51.4)
Inactivated virus vaccine						
Al Kaabi (2021) ¹⁹	WIV04	14	16/12727	11/6361		27·3 (-56·6 to 66·2)
Al Kaabi (2021) ¹⁹	HB02	14	10/12713	10/6361		50·0 (-20·1 to 79·2)
Ella (2021) ²⁶	BBV152	14	13/3248	33/3041		63·1 (30·1 to 80·5)
Subtotal			39/28688	54/15/63		51·0 (24·7 to 68·1)
Overall			027/88287	1205/62334		11.5 (27.8 to 57.1)
$l^2=79.6\%$, heterogeneity p<0.0001			327700307	1333/02334		44.3 (27.0 to 37.4)
· , , ,					0 20 40 60 80 100	
B Symptomatic infection						
	Vaccine name	Days after full vaccination	Vaccination (n/N)	Control (n/N)		Efficacy (95% CI)
		Tuccination	()	(·····)	- I I	
DNA vaccine						
Khobragade (2022)35	ZyCoV-D	28	20/12350	61/12320		67·3 (45·8 to 80·2)
mRNA vaccine						
Ali (2021) ²⁰	mRNA-1273	14	1/2139	7/1042	► <u></u>	93·0 (43·5 to 99·1)
Creech (2022)22	mRNA-1273	14	3/2644	3/853		67·7 (-59·5 to 93·5)
El Sahly (2021) ²⁵	mRNA-1273	14	55/14287	744/14164	H	92·7 (90·4 to 94·4)
Kremsner (2022) ³⁰	CVnCoV	15	83/12851	145/12211	► ■	45·6 (28·8 to 58·4)
Thomas (2021)**	BNT162b2	/	///20998	850/21096		90.9 (88.5 to 92.8)
Walter (2022) ⁵⁰	BN1162b2	7	3/1305	16/663		90.5 (67.4 to 97.2)
<i>I</i> ² =96·3%, heterogeneity p<0·0001			222/54224	1/65/50029		85.5 (63.5 to 94.2)
Viral vector vaccine						
Falsey (2021) ²⁹	A7D1222	15	73/17662	130/8550	⊢ ∎,4	72.8 (63.8 to 79.6)
Halperin (2022) ³¹	Ad5-nCoV	14	77/14 591	211/14 586	⊢ ∎-1	63.5 (52.7 to 71.9)
Kulkarni (2021) ³⁷	SII-ChAdOx1	14	2/1162	2/287		75·3 (-74·6 to 96·5)
Logunov (2021) ³⁸	Gam-COVID-Vac	7	13/14094	47/4601	H-84	91.0 (83.3 to 95.1)
Sadoff (2022)43	Ad26.COV2.S	14	495/19400	1082/19398	HEH	54·3 (49·2 to 58·8)
Voysey (2021)49	AZD1222	14	74/7201	197/7179	⊢ ∎-1	62.6 (51.2 to 71.3)
Subtotal			734/74110	1669/54601	⊢ ♠∔	69.9 (58.2 to 78.4)
<i>I</i> ² =86·5%, heterogeneity p<0·0001						. ,
Inactivated virus vaccine						
Al Kaabi (2021) ¹⁹	WIV04	14	26/12743	48/6369	⊢ ∎-1	72·9 (56·4 to 83·2)
Al Kaabi (2021) ¹⁹	HB02	14	21/12726	47/6368		77·6 (62·6 to 86·6)
Ella (2021) ²⁶	BBV152	14	24/8471	106/8502		77·3 (64·6 to 85·4)
Fadlyana (2021) ²⁸	CoronaVac	14	7/798	18/804	· · · · · · · · · · · · · · · · · · ·	60·8 (6·7 to 83·5)
Palacios (2021) ⁴¹	CoronaVac	14	67/3637	133/3587	⊢ ∎→	50·3 (33·6 to 62·8)
Tanriover (2021) ⁴⁶	CoronaVac	14	9/6559	32/3470	⊢ , −,	85·1 (68·9 to 92·9)
Subtotal			154/44934	384/29100	⊢ •	72·1 (58·9 to 81·1)
I ² =/2·0%, heterogeneity p=0·0032						
Recombinant protein vaccine						6 6 - 6 - 1
Bravo (2022) ²¹	SCB-2019	14	52/5935	155/5806	⊢ ∎-(67·2 (55·2 to 76·0)
Dai (2022) ²³	ZF2001	/	158/12625	580/12568	H H 1	/2·9 (6/·/to //·2)
DUNKIE (2022) ²⁷	NVX-LOV23/3	/ 7	14/1/312	03/0140	· · · ·	oy·o (o1·4 to 94·1)
nayer (2022) ²² Hoath (2021) ³³	COVEP+ASU3	/ 7	33/10115	121/10100		/2.0 (00.0 to 81.4)
Hernández Bernel (2022) ³⁴	Abdala	/	11/10/020	90//019		09.0 (00.0 t0 94.0)
nemanaez-Bernai (2022) ³⁴ Nguyon (2022) ⁴⁰	Abdala	14	11/19089	20/4052		92·3 (05·7 TO 95·8)
Shinda (2021)44		14	93/0042 1E/12E7	09/4052		51.0 (34.0 [0 03.3)
Toledo-Pomani (2022) ⁴⁸	SOREDAMA 02	/	15/135/	29/132/		49.4 (0.1 10 / 2.0) 71.4 (E0.0 to 20.0)
Subtotal	SUBLICATIVA UZ	14	JU/12 J/0	1/11/81 571		76.2 (67.0+0 82.0)
l ² =85.7%, heterogeneity p<0.0001			444/334/3	1411/013/1	· · · · ·	70.3 (07.0 10 02.9)
Overall			1554/280 801	5290/227621	-	76.5 (69.8 to 81.7)
l ² =93.0%, heterogeneity p<0.0001			,_00001	12,22,22,021		, = 5 (=5 5 (0 017)
,, j, p. 1001						
					0 20 40 60 80 100	

(Figure 2 continues on next page)

C Admission to hospital						
	Vaccine name	Days after full vaccination	Vaccination (n/N)	Control (n/N)		Efficacy (95% Crl)
Viral vector vaccine						
Falsey (2021) ²⁹	AZD1222	15	1/17662	8/8550	· · · · · · ·	94·0 (51·7 to 99·2)
Kulkarni (2021) ³⁷	SII-ChAdOx1	14	1/1162	1/287		75·4 (-295 to 98·5)
Sadoff (2021) ⁴²	Ad26.COV2.S	14	2/19514	29/19544		93.1(/1.1 to 98.4)
Subtotal	ALDIZZZ	14	4/50132	47/40157		93.7 (82.1 to 98.3)
l ² =6·2%, heterogeneity p=0·88			4, 50 252	+//+0-5/		557 (02 2 00 50 5)
Inactivated virus vaccine						
Tanriover (2021) ⁴⁶	CoronaVac	14	0/6559	6/3470		95·9 (27·9 to 99·8)
Recombinant protein vaccine	5CP 2010	14	0/5025	0/F006		$0.4.2(0.4 \pm 0.007)$
Hager (2022)	CoVI P+AS03	14	0/5935	2/12.067		80.0 (-316.3 to 99)
Heath (2021) ³³	NVX-CoV2373	7	0/7020	1/7019		66.7 (-718.2 to 98.6)
Subtotal			0/25029	11/24892	⊢ ◆	99.5 (82.3 to 100.0)
<i>I</i> ² =11·7%, heterogeneity p=0·69				C . 100		
Overall			4/81720	64/68519	-	95·4 (88·0 to 98·7)
r=4.0%, heterogeneity p=0.95						
					0 20 40 60 80 100	
D Severe infection						
	Vaccine name	Days after full vaccination	Vaccination (n/N)	Control (n/N)		Efficacy (95% Crl)
DNA vaccine						
Khobragade (2022) ³⁵	ZvCoV-D	28	0/12350	0/12320	÷	0.2 (-4927.8 to 98.0)
mRNA vaccine	_)		-,== 55-	-,		(15-, 5)
El Sahly (2021) ²⁵	mRNA-1273	14	55/14287	744/14164		93·0 (90·8 to 94·7)
Kremsner (2022)36	CVnCoV	15	4/12851	10/12211		62.0 (-21.2 to 88.1)
Thomas (2021)47	BNT162b2	7	1/23040	23/23037	· · · · · · · · · · · · · · · · · · ·	95·7 (67·8 to 99·4)
Walter (2022)50	BNT162b2	7	0/1305	0/663		49·2 (-2464·2 to 99·0)
Subtotal			60/51483	777/50075		91·5 (76·1 to 96·0)
I ² =43·4%, heterogeneity p=0·010						
Viral vector vaccine	1701222	45	0/17/(0)	0/0550		07.2 (50.71, 00.9)
Falsey (2021) ²⁹	AZD1222	15	0/1/662	8/8550		9/2(50.7 to 99.8)
Halperii (2022)* Kulkarni (2021) ³⁷	SIL ChAdOv1	14	0/1162	25/14500		90.0(70.5(0.99.5))
Sadoff (2022) ⁴³	Adde COV2 S	14	56/19/00	205/10308		73.9 (=1149.0 to 39.5) 72.9 (63.6 to 79.8)
Subtotal	//020.0072.5	14	57/52815	238/42821		88.2 (69.6 to 97.5)
l ² =16.8%, heterogeneity p=0.055			57755	-3-7 1		
Inactivated virus vaccine						
Al Kaabi (2021) ¹⁹	WIV04	14	0/12743	1/6369		83·3 (-309·0 to 99·3)
Al Kaabi (2021) ¹⁹	HB02	14	0/12726	1/6368		83·3 (-309·5 to 99·3)
Ella (2021) ²⁶	BBV152	14	1/8471	15/8502		93·3 (49·4 to 99·1)
Fadlyana (2021) ²⁸	CoronaVac	14	0/798	0/804	+ + + + + + + + + + + + + + + + + + + +	-0.8 (-4983.8 to 98.0)
Palacios (2021) ⁴¹	CoronaVac	14	0/4953	6/4870		92.5 (-34.1 to 99.6)
Subtotal $l^2=3.0\%$ beterogeneity $n=0.76$			1/39691	23/26913		96·2 (80·2 to 99·/)
Percombinant protein vaccine						
Bravo (2022) ²¹	SCB-2019	14	0/5935	8/5806	j	94-3 (0-4 to 99-7)
Dai (2022) ²³	ZF2001	7	6/12 625	43/12568	⊢ ∎-4	86.2 (67.5 to 94.1)
Dunkle (2022) ²⁴	NVX-CoV2373	7	0/17312	4/8140)	94.8 (3.0 to 99.7)
Hager (2022) ³⁰	CoVLP+AS03	7	0/12074	3/12067		85·7 (-176·4 to 99·3)
Heath (2021) ³³	NVX-CoV2373	7	0/7020	5/7019	+ + + + + + + + + + + + + + + + + + + +	90·9 (-64·3 to 99·5)
Hernández-Bernal (2022) ³⁴	Abdala	14	1/19689	18/19674		94·5 (58·5 to 99·3)
Nguyen (2022) ⁴⁰	Nanocovax	14	1/8642	7/4052		93·3 (45·6 to 99·2)
Shinde (2021) ⁴⁴	NVX-CoV2373	7	0/1357	1/1327		6/·4 (-700·3 to 98·7)
Ioledo-Romani (2023)** Subtotal	SOREKANA 05	14	5/12578	23/12879		//·8 (41·5 to 91·6)
2=6.4% heterogeneity n=0.77			13/9/232	112/03532		20.2 (05.1 to 20.1)
Overall			121/252571	1150/215661		00.8 (8E.E to 0E.1)
<i>l</i> ² =47·6%, heterogeneity p=0·0030			1/222/12	1130/213001	Ť	30.0 (03.3 10 33.1)
					2 20 40 00 100	

(Figure 2 continues on next page)

the log-transformed RR for symptomatic infection and on the log-transformed OR for severe infections (appendix p 5). We did a sensitivity analysis by only including RCTs reporting both antibody and efficacy data.

Role of the funding source

The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Of the 41053 papers retrieved, 28 eligible efficacy RCTs published in 32 publications were included in this review (figure 1; appendix pp 20–100).¹⁹⁻⁵⁰ A total of 286 915 participants in vaccination groups and 233 236 in placebo groups were involved, with a median follow-up ranging from 1 month to 6 months after last vaccination in individual RCTs. 27 eligible RCTs assessed the efficacy of full vaccination for DNA, mRNA, viral vector, inactivated

E Death						
	Vaccine name	Days after full vaccination	Vaccination (n/N)	Control (n/N)		Efficacy (95% Crl)
mRNA vaccine						
El Sahly (2021) ²⁵	mRNA-1273	14	0/14287	3/14164	÷	85·8 (-174·2 to 99·3)
Viral vector vaccine						
Emary (2021) ²⁷	AZD1222	14	0/4244	0/4290	+	-1·1 (-4995·5 to 98·0)
Halperin (2022) ³¹	Ad5-nCoV	14	0/14591	4/14586		88·9 (-106·3 to 99·4)
Kulkarni (2021) ³⁷	SII-ChAdOx1	14	0/1162	0/287	++	75·3 (-1149·0 to 99·5)
Sadoff (2022) ⁴³	Ad26.COV2.S	14	3/19400	19/19398	· · · · · · · · · · · · · · · · · · ·	84·2 (46·7 to 95·3)
Subtotal			3/39397	23/38561	· · · · · ·	88·4 (56·8 to 97·9)
<i>I</i> ² =5·1%, heterogeneity p=0·96						
Inactivated virus vaccine						
Fadlyana (2021) ²⁸	CoronaVac	14	0/798	0/804	+	-0.8 (-4983.8 to 98.0)
Palacios (2021) ⁴¹	CoronaVac	14	0/4953	1/4870		67·2 (-704·6 to 98·7)
Tanriover (2021) ⁴⁶	CoronaVac	14	0/6559	0/3470		47·1 (-2567·0 to 99·0)
Subtotal			0/12310	1/9144	• · ·	93·5 (-447·4 to 100·0)
l²=2.8%, heterogeneity p=0.91						
Recombinant protein vaccine						
Bravo (2022) ²¹	SCB-2019	14	0/5935	3/5806		86·0 (-170·5 to 99·3)
Dai (2022) ²³	ZF2001	7	2/12625	12/12 568		83·4 (25·9 to 96·3)
Hager (2022) ³⁰	CoVLP+AS03	7	0/10115	0/10106		0·1 (-4935·7 to 98·0)
Hernández-Bernal (2022) ³⁴	Abdala	14	0/19689	4/19674		88·9 (-106·2 to 99·4)
Toledo-Romani (2023) ⁴⁸	SOBERANA 02	14	2/12 578	3/12879		61·6 (-44·7 to 89·8)
Subtotal			4/60942	22/61033		82·8 (48·3 to 95·6)
I ² =6·4%, heterogeneity p=0·75						
Overall			7/126936	49/122902		85·8 (68·7 to 94·6)
I²=3·5%, heterogeneity p=0·94						
					0 20 40 60 20 100	
					0 20 40 00 80 100	

Figure 2: Forest plot for efficacy of full vaccination of SARS-CoV-2 vaccines on preventing infections according to severity of infection and type of vaccine Vaccine efficacy for individual studies was calculated with continuity correction by adding 0.5 to zero-count cells. Crl=credible interval.



Figure 3: Differences in efficacy of different SARS-CoV-2 full vaccinations on preventing infections of different severity, according to vaccine type

Error bars show 95% CI for asymptomatic and symptomatic infection and 95% credible interval for hospital admission, severe infection, and death. Data on asymptomatic infection were not available for DNA vaccine and recombinant protein vaccine; data on hospitalisation were not available for DNA vaccine; data on deaths were not available for DNA vaccine.

virus, and recombinant protein vaccines. Two RCTs compared booster vaccination with no vaccination.

The risk of bias was low in most studies (appendix p 182). The main concern about risk of bias was insufficient blinding of participants and personnel.

Quality of evidence was moderate for all outcomes (appendix p 175).

Nine RCTs evaluated vaccine efficacy against asymptomatic infection.^{19,20,22,25,26,37,43,45,49} The combined efficacy was $44 \cdot 5\%$ (95% CI $27 \cdot 8-57 \cdot 4$) with high heterogeneity ($I^2=79 \cdot 6\%$, $p<0 \cdot 0001$): $56 \cdot 5\%$ (95% CI $46 \cdot 2-64 \cdot 9$) for mRNA vaccines, $32 \cdot 1\%$ ($5 \cdot 3-51 \cdot 4$) for viral vector vaccines, and $51 \cdot 0\%$ ($24 \cdot 7-68 \cdot 1$) for inactivated vaccines (figures 2, 3).

27 RCTs investigated vaccine efficacy against symptomatic infection.^{19-26,28-31,33-38,40,41,43,44,46-50} The combined efficacy was 76.5% (95% CI 69.8-81.7) with high heterogeneity (12=93.0%, p<0.0001): 67.3% (95% CI 45.8-80.2) for the DNA vaccine, 85.5% (63.5-94.2) for mRNA vaccines, 69.9% (58.2-78.4) for viral vector vaccines, 72.1% (58.9-81.1) for inactivated vaccines, and 76.3% (67.0-82.9) for recombinant protein vaccines (figures 2, 3). Vaccine efficacy for preventing symptomatic infection was 78.2% (64.0-86.8) for alpha (B.1.1.7) variants of concern, 33.4% (7.1-52.2) for beta (B.1.351) variants of concern, 73.1% (31.5-89.4) for gamma (P.1) variants of concern, and 67.0% (50.0-78.2) for delta (B.1.617.2) variants of concern. There was significant waning of efficacy over time (p=0.0007), with an average decrease of 13.6% (95% CI 5.5-22.3) per month after full vaccination (figure 4).

Eight RCTs assessed vaccine efficacy against COVID-19 related hospital admission.^{21,29,30,33,37,42,46,49} The combined efficacy was 95.4% (95% CrI 88.0-98.7) with modest heterogeneity (I^2 =4.0%, p=0.95). All types of vaccines showed high efficacy against hospital admission (figures 2, 3).

22 RCTs reported the efficacy of different vaccines against severe infection.^{19,21,23–26,28–31,40,41,43,44,47,48,50} The combined efficacy was 90.8% (95% CrI 85.5-95.1) with moderate heterogeneity ($I^2=47.6\%$, p=0.0030): 91.5% (95% CrI 76.1-96.0) for mRNA vaccines, 88.2% (69.6-97.5) for viral vector vaccines, 96.2% (80.2-99.7) for inactivated virus vaccines, and 90.5% (82.1-96.1) for recombinant protein vaccines (figures 2, 3). Only one RCT was available for the DNA vaccine, with no severe infections in both groups. In general, a moderate efficacy in preventing symptomatic infections was related to a higher efficacy in preventing severe infections (appendix p 184).

13 RCTs assessed the efficacy of vaccination against COVID-19 related death.^{21,23,25,27,28,30,31,34,37,41,34,648} The combined efficacy was $85 \cdot 8\%$ (95% CrI $68 \cdot 7$ to $94 \cdot 6$) with modest heterogeneity ($I^2=3 \cdot 5\%$, $p=0 \cdot 94$): $85 \cdot 8\%$ (95% CrI –174 · 2 to $99 \cdot 3$) for mRNA vaccines, $88 \cdot 4\%$ ($56 \cdot 8$ to $97 \cdot 9$) for viral vector vaccines, $93 \cdot 5\%$ (–447 · 4 to $100 \cdot 0$) for inactivated vaccines, and $82 \cdot 8\%$ ($48 \cdot 3$ to $95 \cdot 6$) for recombinant protein vaccines (figures 2, 3).

Characteristics of studies about antibody measurements are in the appendix (pp 101–171). We found a non-linear dose–response relationship between each type of antibody and efficacy against both symptomatic and severe infections (all p values for coefficients were <0.0001) but there remained large unexplained variations in the relationship (figure 5).⁵¹ As T-cell immunity measures differed substantially across trials, it was not feasible to assess the T-cell immunity–efficacy relationship in this Article (appendix pp 172–74).

The funnel plot and Egger's test showed no clear evidence of publication bias (appendix p 183). There was insufficient evidence to suggest whether efficacy against SARS-CoV-2 differed according to type of vaccine, age of the vaccinated, and between-dose interval (all p>0.05; appendix pp 177–79). A series of sensitivity analyses showed similar results to the main findings (appendix pp 180–81).

Two RCTs assessed the efficacy of a booster with Ad26. COV2.S (Johnson & Johnson; 75.6%, 95% CI 55.5-87.5) or SOBERANA-02 Plus (Instituto Finlay de acunas, Havana; 92.0%, 80.4-96.7) vaccines against symptomatic infection, with scarce or no data on other outcomes (appendix pp 12–18).^{32,48}

Discussion

In this systematic review and meta-analysis, we found moderate-quality evidence that SARS-CoV-2 vaccines could reduce the risk of SARS-CoV-2 infections and effectively prevent most severe infections and deaths. The magnitude of vaccine efficacy could vary in different populations as suggested by the moderate-to-high heterogeneity across RCTs. Efficacy against symptomatic infection waned over time after full vaccination was completed but can be enhanced by a booster. We found a non-linear antibody–efficacy relationship but there



Figure 4: Change of vaccine efficacy in preventing symptomatic infection after full vaccination Error bars show 95% Cl.

remained large heterogeneity in the efficacy that cannot be explained by the antibody concentrations.

Mild infections are the main source of SARS-CoV-2 transmission. Successful prevention of mild infections is crucial for containing the pandemic. However, the efficacy of vaccination in preventing asymptomatic infections was suboptimal and could well be lower than 50%, suggesting that the vaccines alone are unlikely to be able to stop the



Figure 5: Dose-response relationship of three SARS-CoV-2 antibodies with efficacy of full vaccination for preventing symptomatic infections (A–C) and severe infections (D–F)

An example of prediction. Thiruvengadam and colleagues²¹ showed that the neutralising antibody titres 61 days after the second vaccine dose of ChAdOx1 nCoV-19 (adenovirus-vectored vaccine) were 599-4 (95% CI 376-9–953-2), which converts to an SMD of 3-96. Using the formula efficacy=(1-e^{-0.2004-SMD})×100%, an efficacy of 67-1% for preventing symptomatic infection is obtained, which is close to the efficacy estimate of 63-1% given in the study. Where n₁ is the number of trials providing both efficacy and antibody data and n₂ is the number of trials providing efficacy data only, with corresponding antibody data reported in previous phase trials: (A) n₁=13, n₂=14; (B) n₁=9, n₂=8; (C) n₁=6, n₂=8; (D) n₁=9, n₂=13; (E) n₁=6, n₂=8; (F) n₁=5, n₂=6. RBD=receptor binding domain.

pandemic. In addition, vaccine efficacy against symptomatic infections seemed lower than that estimated in other meta-analyses^{4,9} of earlier RCTs done in the wild-type strain predominant period (about 95% for mRNA vaccines and 80% for virus vector vaccines). The evolution of SARS-CoV-2 variants might be a cause for the compromised efficacy,⁵ but confirming this based on indirect comparisons from different RCTs will be difficult due to the large unexplained heterogeneity and incomplete coverage of people who are infected for whole-genome sequencing in RCTs.

Given the moderate and variable efficacy of vaccines in preventing mild infections, the primary goal of SARs-CoV-2 vaccination strategies should be reset to reducing the risk of severe COVID-19 illness and deaths. Although mild infection has become more common and fatality is much lower during the omicron pandemic, the number of severe infections can still be large if many people are infected in a short period.⁵² Surges in severe infections could also stress hospital systems, negatively affecting health care, which in turn could further increase the risk of death from COVID-19.⁵³ Vaccination is therefore still crucial as it can prevent about 90% of severe COVID-19 illness and deaths. These findings are also reconfirmed in large real-world observational studies.⁵⁴⁻⁵⁶

In line with a meta-analysis of observational studies,⁶ we found that overall vaccine efficacy decreased in the first 6 months after full vaccination was completed in RCTs. However, the peaking time and waning rate might vary by different vaccines and booster vaccination might compensate for the waning of efficacy, which was also supported by observational studies.^{57,58} For severe infections, data from RCTs were insufficient to establish the change in the efficacy over time, but observational studies suggested that the effectiveness against severe COVID-19 remained high by 6 months after full vaccination.⁶ Given the evidence for waning efficacy, it is important to time vaccination in relation to an anticipated outbreak.

Although observational studies found that the protection against symptomatic and severe infections differed by types of vaccines,⁵⁹ currently available RCTs provided no strong evidence to support this difference. In fact, we found significant heterogeneity in vaccine efficacy across individual RCTs and the heterogeneity was high even in RCTs on the same type of vaccines. This heterogeneity suggests that the variability in vaccine efficacy was more likely a result of a total effect of differences in trial design, population characteristics, sample size, outcome detection, duration after vaccination, and other factors, than the types of vaccines themselves.

SARs-CoV-2 antibodies elicited by vaccines are commonly used to predict or compare the magnitude of vaccine efficacy. The validity of such predictions has, however, not been firmly established. Indeed, our exploratory analysis found that a higher concentration of neutralising, anti-spike, or anti-RBD antibody titres, regardless of the working mechanisms of the vaccines, was associated with a higher efficacy, particularly for preventing severe infections. However, the efficacy was not proportional to concentrations of antibodies. These findings agreed with the dose–response relationships shown within the only study available at the time of review. 10

Although the antibody-efficacy association might truly exist, 10,60,61 precise prediction of vaccine efficacy using the association seems difficult as there remains large variability in the efficacy, which cannot be explained by the antibody concentrations. The antibody-efficacy association might differ by population characteristics, assays, types of vaccines, and time after vaccination. Even within the same study, however, large unexplained variations were also found in the antibody-efficacy association.¹⁰ Therefore, any efforts to use antibody concentrations to predict efficacy should be cautious, particularly when antibodies and efficacy are measured from different populations. Better prediction could be achieved if other potential factors in the prediction model are accounted for, rather than antibody concentrations alone.

T-cell immunity was also proposed as a factor in predicting vaccine efficacy.⁶² However, the dose relationship between T-cell concentrations and efficacy has yet to be established and this relationship is difficult to assess on current available trial data given non-standardised measures of T-cell immunity (appendix pp 168–70). Before more reliable evidence on the T-cell immunity–efficacy relationship becomes available, simply labelling strong (or weak) T-cell response found in a group of people as high (or low) efficacy should also be cautioned against.

To our knowledge, this is the most comprehensive investigation of all currently available vaccine efficacy trials and paired immunogenicity–efficacy data to assess the vaccine efficacy and the antibody–efficacy association. Due to data on severe SARs-CoV-2 infections being extremely rare in individual trials, our meta-analysis provided considerably more robust evidence on the efficacy against severe infections than individual trials have. The findings on the antibody–efficacy relationship are also highly valuable as the paired data collected repeatedly over time within a trial are unlikely to become available in the near future or at all.

There are some limitations in our review. First, considerable heterogeneity exists in the efficacy of vaccination for preventing symptomatic infections and moderate heterogeneity for preventing severe infections. Most of the heterogeneity is probably a result of trial-design factors and makes comparing the efficacy of different types of vaccines evaluated in separate trials difficult, although current trial evidence is insufficient to support such differences. Second, many limitations in our study originated from individual trials, for example insufficient data on the SARS-CoV-2 variants, inconsistent definitions of infection severity, the paucity of information on environmental factors, and partial coverage of study population for nucleic acid testing. These factors could

also contribute to the unexplained heterogeneity and potentially resulted in biases in vaccine efficacy estimates. Finally, ecological bias might exist in our meta-regression using aggregated study-level data as there could be other factors that can affect both the antibody concentration and efficacy, such as types of vaccines and predominant variants of SARS-CoV-2. However, due to the low number of studies within each category of these factors, we were not able to do a meta-regression stratified by these factors. Individual participant data are needed to better assess this relationship; however, these data are unlikely to be made available.

This Article has some important implications for future research. First, the large evidence base summarised in our review provides an irreplaceable reference for comparisons with and interpretation of new trials in the development of new vaccines and booster regimens, including those against omicron variants. For example, a moderate efficacy in preventing symptomatic infections seems to be related to a higher efficacy in preventing severe infections. Waning of efficacy also probably exists for new vaccines against new variants of the virus. Immunogenicity in people vaccinated with a booster or a new vaccine might not accurately predict vaccine efficacy.

Second, this study suggested that uncertainties remain over vaccine efficacy beyond 6 months of the last vaccination and efficacy against omicron infections. The efficacy according to type of vaccines, age of the vaccinated, between-dose interval, and variant of the virus remained unsatisfactorily answered due to the small number of trials available and large unexplained between-trial heterogeneity. Although a booster can enhance efficacy, the best timing and the best regimen for a booster remain to be investigated.

Third, this study has also identified some important gaps, which could guide the design of future trials on SARS-CoV-2 vaccines. To enable valid comparison of the results from different trials, assays and timing for immunogenicity measurement should be standardised. The relationships of vaccine efficacy with humoral and cellular immune responses should be further confirmed. To reduce detection bias, surveillance testing for SARS-CoV-2 infection should cover all the study population. Since vaccine efficacy might vary for different SARS-CoV-2 variants, genome sequencing should be done to confirm the variants, particularly for trials done through different periods of predominant variants. Future trials need to increase the power if they aim to assess comparative efficacy between vaccine regimens or between different participant subgroups. Since it is not always feasible to conduct such large-scale RCTs, real-world studies as an alternative could be done to timely address some of the important questions for decision making.

Contributors

J-LT, FS, Z-YY, and Z-RY conceived the research question and designed the study. Z-RY and Y-WJ did the literature search. Z-RY, Y-WJ, F-XL,

DL, T-FL, Z-YZ, CW, Q-YJ, X-ML, Y-XJ, and FS screened articles. Z-RY, Y-WJ, F-XL, DL and T-FL read the full texts for eligibility. Z-RY, Y-WJ, and F-XL extracted data from the original trials. DL and T-FL evaluated the risk of bias. Y-WJ and Z-RY did the analyses and evaluated the quality of evidence. J-IT, FS, Z-YY, Z-RY, Y-WJ, F-CZ, and Z-JF contributed to the interpretation of the results. Z-RY and Y-WJ wrote the first draft of the manuscript. J-IT, FS, and Z-YY critically revised the manuscript. All authors acknowledge full responsibility for the analyses and interpretation of the report. All authors have read and approved the final manuscript. J-LT is the guarantor. The corresponding authors attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Declaration of interests

We declare no competing interests.

Data sharing

All data included were derived from publicly available documents cited in the references. Extracted data are all presented in this manuscript and appendix.

Acknowledgments

This work was supported by the Shenzhen Science and Technology Programs (grant numbers KQTD20190929172835662, RKX20210901150004012, and JSGG20220301090202005).

References

- Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. *Immunity* 2021; 54: 1636–51.
- 2 Higdon MM, Wahl B, Jones CB, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis 2022; 9: ofac138.
- 3 Cheng H, Peng Z, Luo W, et al. Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis. *Vaccines (Basel)* 2021; 9: 582.
- 4 Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. *Vaccines (Basel)* 2021; 9: 467.
- 5 Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. *BMC Med* 2022; 20: 200.
- 6 Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and metaregression. *Lancet* 2022; 399: 924–44.
- 7 WHO. Strategy to achieve global COVID-19 vaccination by mid-2022. 2021. https://cdn.who.int/media/docs/default-source/ immunization/covid-19/strategy-to-achieve-global-covid-19vaccination-by-mid-2022.pdf (accessed July 11, 2022).
- 8 Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021; 27: 205–11.
- 9 Chen X, Chen Z, Azman AS, et al. Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis. *Clin Infect Dis* 2022; 74: 734–42.
- 10 Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 2021; 27: 2032–40.
- 11 Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021; **372**: n160.
- 12 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. 2011. https:// handbook-5-1.cochrane.org/ (accessed July 11, 2022).
- 13 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**: 924–26.
- 14 Günhan BK, Röver C, Friede T. Random-effects meta-analysis of few studies involving rare events. *Res Synth Methods* 2020; 11: 74–90.
- 15 Gelman A. Prior distributions for variance parameters in hierarchical models. *Bayesian Anal* 2006; 1: 515–34.
- 16 Xu C, Furuya-Kanamori L, Zorzela L, Lin L, Vohra S. A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. J Clin Epidemiol 2021; 135: 70–78.

- 17 Efthimiou O. Practical guide to the meta-analysis of rare events. Evid Based Ment Health 2018; 21: 72–76.
- 18 Meng XL. Posterior predictive p-values. Ann Stat 1994; 22: 1142–60.
- 19 Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 2021; 326: 35–45.
- 20 Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021; 385: 2241–51.
- 21 Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. *Lancet* 2022; **399:** 461–72.
- 22 Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 COVID-19 vaccine in children 6 to 11 years of age. N Engl J Med 2022; 386: 2011–23.
- 23 Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimerbased COVID-19 vaccine ZF2001 in adults. N Engl J Med 2022; 386: 2097–111.
- 24 Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med 2022; 386: 531–43.
- 25 El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021; 385: 1774–85.
- 26 Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet* 2021; **398**: 2173–84.
- 27 Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet* 2021; **397**: 1351–62.
- Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. *Vaccine* 2021; 39: 6520–28.
- 29 Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021; 385: 2348–60.
- 30 Hager KJ, Pérez Marc G, Gobeil P, et al. Efficacy and safety of a recombinant plant-based adjuvanted COVID-19 vaccine. N Engl J Med 2022; 386: 2084–96.
- 31 Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. *Lancet* 2022; 399: 237–48.
- 32 Hardt K, Vandebosch A, Sadoff J, et al. Efficacy and safety of a booster regimen of Ad26.COV2.S vaccine against COVID-19. *Lancet Infect Dis* 2022; 22: 1703–15.
- 33 Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med 2021; 385: 1172–83.
- 34 Hernández-Bernal, Ricardo-Cobas MC, Martín-Bauta Y, et al. A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study). EClinicalMedicine 2022; 46: 101383.
- 35 Khobragade A, Bhate S, Ramaiah V, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. *Lancet* 2022; **399**: 1313–21.
- 36 Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. *Lancet Infect Dis* 2022; 22: 329–40.
- 37 Kulkarni PS, Padmapriyadarsini C, Vekemans J, et al. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. *EClinicalMedicine* 2021; 42: 101218.

- 38 Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021; **397**: 671–81.
- 39 Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384: 1885–98.
- 40 Nguyen TP, Do Q, Phan LT, et al. The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled phase 3 trial. *medRxiv* 2022; published online March 23. https://doi.org/10.1101/2022.03.22.22272739 (preprint).
- 41 Palacios R, González Patiño E, de Oliveira Piorelli R, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study. *Trials* 2021; 21: 853.
- 42 Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of singledose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021; 384: 2187–201.
- 43 Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med 2022; 386: 847–60.
- 44 Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384: 1899–909.
- 45 Sobieszczyk ME, Falsey AR, Robb ML, et al. LB6 asymptomatic infection and duration of viral shedding in symptomatic breakthrough infections in a phase 3 study of AZD1222 (ChAdOx1 nCoV-19). Open Forum Infect Dis 2021; 8 (suppl 1): S804.
- 46 Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* 2021; **398**: 213–22.
- 47 Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. *N Engl J Med* 2021; 385: 1761–73.
- 48 Toledo-Romaní ME, García-Carmenate M, Valenzuela-Silva C, et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-2 PLUS: a double-blind, randomised, placebo-controlled phase 3 clinical trial. *Lancet Reg Health Am* 2023; 18: 100423.
- 49 Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; 397: 881–91.
- 50 Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med 2022; 386: 35–46.

- 51 Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.6172) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. *Lancet Infect Dis* 2022; 22: 473–82.
- 52 Taylor CA, Whitaker M, Anglin O, et al. COVID-19-associated hospitalizations among adults during SARS-CoV-2 delta and omicron variant predominance, by race/ethnicity and vaccination status - COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 466–73.
- 53 French G, Hulse M, Nguyen D, et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic - United States, July 2020-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1613–16.
- 54 Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386: 1532–46.
- 55 Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet* 2022; **399**: 1303–12.
- 56 Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022. *Euro Surveill* 2022; 27: 2200077.
- 57 Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. *BMJ* 2022; 377: e069989.
- 58 Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. *Lancet Infect Dis* 2022; 22: 1114–16.
- 59 Premikha M, Chiew CJ, Wei WE, et al. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. *Clin Infect Dis* 2022; 75: 1442–45.
- 60 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; 27: 1205–11.
- 61 Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* 2022; 3: e52–61.
- 62 Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science 2022; 377: 821–22.